As of 2025-11-13, the Intrinsic Value of Enorama Pharma AB (ERMA.ST) is 19.87 SEK. This ERMA.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 2.84 SEK, the upside of Enorama Pharma AB is 599.70%.
The range of the Intrinsic Value is 12.48 - 133.44 SEK
Based on its market price of 2.84 SEK and our intrinsic valuation, Enorama Pharma AB (ERMA.ST) is undervalued by 599.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 12.48 - 133.44 | 19.87 | 599.7% |
| DCF (Growth 10y) | 12.66 - 137.46 | 20.48 | 621.3% |
| DCF (EBITDA 5y) | 13.64 - 76.68 | 23.90 | 741.7% |
| DCF (EBITDA 10y) | 12.70 - 94.53 | 21.01 | 639.7% |
| Fair Value | -4.72 - -4.72 | -4.72 | -266.05% |
| P/E | (8.79) - 87.06 | 34.37 | 1110.3% |
| EV/EBITDA | (2.19) - 53.11 | 21.69 | 663.7% |
| EPV | (0.08) - (1.51) | (0.79) | -128.0% |
| DDM - Stable | (5.63) - (10.47) | (8.05) | -383.5% |
| DDM - Multi | 44.23 - 66.03 | 53.12 | 1770.5% |
| Market Cap (mil) | 211.84 |
| Beta | 1.12 |
| Outstanding shares (mil) | 74.59 |
| Enterprise Value (mil) | 209.32 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.42% |
| Cost of Debt | 121.37% |
| WACC | 53.20% |